Literature DB >> 30940668

Tc-99m HYNIC-TOC scintigraphy in dedifferentiated thyroid cancer.

Kanhaiyalal Agrawal1, P Sai Sradha Patro1, C Preetam2.   

Abstract

There is literature evidence showing utility of somatostatin receptor (SSTR) positron emission tomography-CT (PET-CT) imaging in differentiated thyroid cancer with Thyroglobulin Elevated and Negative Iodine Scan (TENIS). These patients are less benefited with I-131 therapy and surgery remains only curable option if disease could be localised. If surgery is not feasible, other therapeutic options are not promising. However, if these patients show strongly positive SSTR imaging, then possibility of peptide receptor radionuclide therapy may be explored. As SSTR PET-CT imaging is expensive and not widely available, Technetium-99m (Tc-99m) hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC), which is a Single photon emission computed tomography (SPECT) tracer, can be used. We are documenting a case of raised serum thyroglobulin antibody and negative I-131 whole body scan with disease recurrence localised on Tc-99m HYNIC-TOC scan. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  dedifferentiated; endocrine system; thyroid cancer; thyroid disease

Mesh:

Substances:

Year:  2019        PMID: 30940668      PMCID: PMC6453278          DOI: 10.1136/bcr-2018-227910

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  6 in total

1.  Prospective evaluation of (68)Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative (131)I-whole body scan: comparison with (18)F-FDG PET-CT.

Authors:  Parveen Kundu; Sneh Lata; Punit Sharma; Harmandeep Singh; Arun Malhotra; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

Review 2.  Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC).

Authors:  Carole A Spencer
Journal:  J Clin Endocrinol Metab       Date:  2011-09-14       Impact factor: 5.958

3.  Somatostatin receptor expression in thyroid disease.

Authors:  Helen Atkinson; James A England; Amy Rafferty; Vim Jesudason; Karen Bedford; Laszlo Karsai; Stephen L Atkin
Journal:  Int J Exp Pathol       Date:  2013-06       Impact factor: 1.925

Review 4.  Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues.

Authors:  Ali Salavati; Ameya Puranik; Harshad R Kulkarni; Hendra Budiawan; Richard P Baum
Journal:  Semin Nucl Med       Date:  2016-05       Impact factor: 4.446

5.  99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans.

Authors:  Michael Gabriel; Franz Froehlich; Clemens Decristoforo; Christian Ensinger; Eveline Donnemiller; Elisabeth von Guggenberg; Dirk Heute; Roy Moncayo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-11-19       Impact factor: 9.236

6.  Utility of (99m)Tc-Hynic-TOC in 131I Whole-Body Scan Negative Thyroid Cancer Patients with Elevated Serum Thyroglobulin Levels.

Authors:  Ajit S Shinto; K K Kamaleshwaran; Madhav Mallia; Aruna Korde; Grace Samuel; Sharmila Banerjee; Pavanasam Velayutham; Suresh Damodharan; Madhu Sairam
Journal:  World J Nucl Med       Date:  2015 May-Aug
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.